131 related articles for article (PubMed ID: 36655529)
1. CYP1B1: A Promising Target in Cancer Drug Discovery.
Fabris M; Luiza Silva M; de Santiago-Silva KM; de Lima Ferreira Bispo M; Goes Camargo P
Anticancer Agents Med Chem; 2023; 23(9):981-988. PubMed ID: 36655529
[TBL] [Abstract][Full Text] [Related]
2. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
[TBL] [Abstract][Full Text] [Related]
3. The Activation of Procarcinogens by CYP1A1/1B1 and Related Chemo-Preventive Agents: A Review.
Li Y; Cui J; Jia J
Curr Cancer Drug Targets; 2021; 21(1):21-54. PubMed ID: 33023449
[TBL] [Abstract][Full Text] [Related]
4. Dihydrotanshinone I-Induced CYP1 Enzyme Inhibition and Alteration of Estradiol Metabolism.
Liu Y; Chen Y; Zhang J; Ran G; Cheng Z; Wang X; Liao Y; Mao X; Peng Y; Li W; Zheng J
Drug Metab Dispos; 2024 Feb; 52(3):188-197. PubMed ID: 38123940
[TBL] [Abstract][Full Text] [Related]
5. Nitidine Chloride-Induced CYP1 Enzyme Inhibition and Alteration of Estradiol Metabolism.
Mao X; Wang J; Wang Q; Yang L; Li Y; Lin H; Peng Y; Zheng J
Drug Metab Dispos; 2019 Aug; 47(8):919-927. PubMed ID: 31147316
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites.
Chang YP; Huang CC; Shen CC; Tsai KC; Ueng YF
Drug Metab Pharmacokinet; 2015 Oct; 30(5):374-83. PubMed ID: 26403084
[TBL] [Abstract][Full Text] [Related]
7. DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.
Cui J; Zhang X; Huang G; Zhang Q; Dong J; Sun G; Meng Q; Li S
Mol Pharm; 2019 Jan; 16(1):409-421. PubMed ID: 30481041
[TBL] [Abstract][Full Text] [Related]
8. Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment.
D'Uva G; Baci D; Albini A; Noonan DM
Cancer Treat Rev; 2018 Feb; 63():1-18. PubMed ID: 29197745
[TBL] [Abstract][Full Text] [Related]
9. Characterization of differences in substrate specificity among CYP1A1, CYP1A2 and CYP1B1: an integrated approach employing molecular docking and molecular dynamics simulations.
Kesharwani SS; Nandekar PP; Pragyan P; Rathod V; Sangamwar AT
J Mol Recognit; 2016 Aug; 29(8):370-90. PubMed ID: 26916064
[TBL] [Abstract][Full Text] [Related]
10. A new class of CYP1B1 inhibitors derived from bentranil.
Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D
Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966
[TBL] [Abstract][Full Text] [Related]
11. Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.
Wang Z; Chen Y; Drbohlav LM; Wu JQ; Wang MZ
J Biomol Screen; 2016 Dec; 21(10):1090-1099. PubMed ID: 28139960
[TBL] [Abstract][Full Text] [Related]
12. Oroxylin A, a methylated metabolite of baicalein, exhibits a stronger inhibitory effect than baicalein on the CYP1B1-mediated carcinogenic estradiol metabolite formation.
An D; Song Z; Yi Y; Zhang Q; Liu J; Zhang Y; Zhou J; Zhao G; Cong D; Li N; Lu Y; Chen X; Zhao D
Phytother Res; 2019 Apr; 33(4):1033-1043. PubMed ID: 30680817
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and docking studies of trans-stilbene methylthio derivatives as cytochromes P450 family 1 inhibitors.
Wierzchowski M; Dutkiewicz Z; Gielara-Korzańska A; Korzański A; Teubert A; Teżyk A; Stefański T; Baer-Dubowska W; Mikstacka R
Chem Biol Drug Des; 2017 Dec; 90(6):1226-1236. PubMed ID: 28632937
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
[TBL] [Abstract][Full Text] [Related]
15. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids.
Androutsopoulos VP; Papakyriakou A; Vourloumis D; Spandidos DA
Bioorg Med Chem; 2011 May; 19(9):2842-9. PubMed ID: 21482471
[TBL] [Abstract][Full Text] [Related]
16. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs.
Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F
Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors and prodrugs targeting CYP1: a novel approach in cancer prevention and therapy.
Cui J; Li S
Curr Med Chem; 2014; 21(5):519-52. PubMed ID: 24083611
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin.
Chang TK; Chen J; Yang G; Yeung EY
J Pineal Res; 2010 Jan; 48(1):55-64. PubMed ID: 19919601
[TBL] [Abstract][Full Text] [Related]
19. Hydration and Structural Adaptations of the Human CYP1A1, CYP1A2, and CYP1B1 Active Sites by Molecular Dynamics Simulations.
Dutkiewicz Z; Mikstacka R
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511239
[TBL] [Abstract][Full Text] [Related]
20. In silico guided designing of optimized benzochalcones derivatives as potent CYP1B1 inhibitors: An integrated in vitro and ONIOM study.
Sharma H; Raju B; Narendra G; Kumar M; Verma H; Sharma B; Tung GK; Kumar Jain S; Brás NF; Silakari O
J Mol Graph Model; 2023 Mar; 119():108390. PubMed ID: 36502606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
